Avianax's story began in 2002, when West Nile Virus became endemic in the environment and there was no protection for the domestic goose industry.  Through various experiments done at the University of North Dakota and Schiltz Goose Farms Inc, we found that purified antibodies administered through the watering system were an economical source of protection and would save the goose industry.  We began to wonder if goose antibodies could be effective therapeutic agent in other diseases and animals.  



Next, a group of investors joined forces with the University of North Dakota and formed Avianax LLC (a public/private entity) to explore the possibilities.  To prove up the concept of a rapid antibody production platform, 
Avianax had to design and construct the only Specific Pathogen Free facility in North America used for the sole purpose of producing goose antibodies on a large scale.  Additionally, we developed and patented a scalable purification process to isolate antibodies from very lipid-rich goose egg yolks.  Through the combination of a large SPF facility and dedicated purification laboratory, Avianax has shown the flexibility to produce antibodies from a wide variety of antigens on both large and small scales.  


​Since its formation, Avianax has worked with many viral diseases including: West Nile Virus, Rabies, Canine Parvovirus, Rotavirus, Coronavirus, Dengue Fever, Marburg, Guanarito, Junin, Sabia, Machupo, Andes, Hantaan, Puumala, Sin Nombre, Avian Influenza, and HIV. In addition to viral diseases we have also conducted research against Plasmodium falciparum (Malaria), several surface proteins, peptides, and toxins.


Please click here for information on our research.